Insider Activity for Investors: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)


Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) lost -7.94 Percent and closed its previous trading session at $8.7. The stock traded with the average Volume of 619.49 Million at the end of last session.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has the Market Capitalization of 324.42 Million. The Stock has its 52-week High of $9.75 and 52-Week Low of $1.88 and it touched its 52-week high on 02/13/18 and 52-Week Low on 02/24/17.

The company reported its last earnings Actual EPS of $-0.16/share. While, the analyst predicted that the company could provide an EPS of $-0.22/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.06/share which shows an Earnings Surprise of 27.3 Percent.

Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 11.21% where SMA50 and SMA200 are 22.39% and 55.8% respectively.

The company shows its Return on Assets (ROA) value of -42%. The Return on Equity (ROE) value stands at -221.8%. While it’s Return on Investment (ROI) value is -91%.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) currently has a Weekly Volatility of 10.11% percent while its Monthly Volatility is at 6.54% percent. While talking about Performance of the Stock, Pieris Pharmaceuticals, Inc. currently has a Weekly performance of 12.55%, monthly performance percentage is 25.72 percent, Quarterly performance is 56.76 percent, 6 months performance shows a percent value of 84.32% and Yearly Performance is 304.65 percent.

Company Profile:

Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.